November 11, 2015Expert Opinion on Pharmacotherapy
Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Key result
Phase III trials confirm that edoxaban is non-inferior to well-managed warfarin for stroke prevention in non-valvular atrial fibrillation in terms of both efficacy and safety.
Why the study?
Does edoxaban prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Population
Patients with non-valvular atrial fibrillation
Comparison
Edoxaban vs Warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Broadens anticoagulation choices for non-valvular AF; confirms non-inferiority to warfarin and extends NOAC evidence base.
Structured PICO
Does edoxaban prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
P
Population
Patients with non-valvular atrial fibrillation
I
Intervention
Edoxaban
C
Comparator
Warfarin
O
Outcome
Stroke and systemic embolism preventionhard clinical
Edoxaban is a non-inferior alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, offering fewer food and drug interactions.
Limitations
- Lacking evidence in areas where NOAC use remains controversial
- Need for real-world data to confirm effectiveness and safety for chronic anticoagulation
- Lack of evidence in areas where NOAC use remains controversial
- Need for real-world data
Cite This Study
Dzeshka et al. (2015) conducted a review in non-valvular atrial fibrillation. Edoxaban vs. warfarin was evaluated on stroke and thromboembolism prevention. Phase III trials confirm that edoxaban is non-inferior to well-managed warfarin for stroke prevention in non-valvular atrial fibrillation in terms of both efficacy and safety.